Industry Insights
Sep 14, 2026 · 1 min read · 86,183 views
Exclusive: ARCH, Parker Institute build next big oncology bet with suite of programs and startup acquisition
I
Isabella Hart
Editorial · Sep 14, 2026
Some of the biggest names in oncology R&D have been quietly consolidating assets, money and programs under a new startup called Medici Therapeutics, Endpoints News has learned. The
← Previous
Olema, Novartis ink another agreement, this time for a late-stage breast cancer trial
Next →
The most exciting biotech startups of 2026: How we selected this year's list
